Os Therapies INC

OS Therapies Incorporated has terminated its At Market Issuance Sales Agreement with B. Riley Securities and JonesTrading, effective July 28, 2026, after selling a fraction of the available shares.

OS Therapies Incorporated filed an amendment to its Form 8-K to include a side letter dated June 30, 2026, with Leonite Fund I, LP, clarifying terms related to a private placement transaction.

OS Therapies Incorporated announced the closing of a $5.25 million registered direct offering, raising approximately $4.7 million in net proceeds to fund clinical development and research.

OS Therapies Incorporated filed a prospectus supplement covering the resale of up to 10,529,417 shares of common stock by selling stockholders, supported by a legal opinion affirming their validity.

OS Therapies Incorporated announced a private placement of convertible notes and warrants, raising $2 million to fund clinical development and R&D programs.

OS Therapies Incorporated has extended its inducement offer for existing warrant holders to exercise their warrants at a reduced price until March 2, 2026.

OS Therapies Inc. reported its first quarter 2026 financial results, highlighting significant increases in research and development expenses and continued net losses, while advancing its OST-HER2 therapy towards regulatory submissions.

OS Therapies announced positive two-year survival data for its lead cancer therapy OST-HER2, while reporting increased losses and a going concern warning.

OS Therapies reported a significantly wider net loss in Q2 2025, driven by increased R&D and administrative costs, while securing new capital and advancing its lead cancer immunotherapy.

OS Therapies Incorporated announces its financial results for the quarter ended March 31, 2025, showcasing progress in its clinical trials and recent asset acquisitions.

OS Therapies reported its financial results for the third quarter of 2024, highlighting its recent IPO and ongoing clinical trial for Osteosarcoma.

OS Therapies Incorporated reported its financial results for the quarter ended June 30, 2024, noting a net loss but also highlighting its recent IPO and ongoing clinical trial for Osteosarcoma therapy.

OS Therapies provides an update on its financial standing, clinical trial outcomes, and strategic moves, including an acquisition, in its annual report.

Theodore F. Search, a Director and 10% owner of OS Therapies Inc., was granted options to purchase 50,000 shares of common stock.

OS Therapies Inc. Director John Ciccio received a grant of 50,000 stock options with an exercise price of $1.34, vesting in one year.

OS Therapies Inc.'s Chief Financial Officer, Christopher P. Acevedo, was granted 100,000 stock options with a $1.34 exercise price.

OS Therapies' Chief Medical and Scientific Officer, Robert Petit, was granted options to purchase 100,000 shares of common stock at an exercise price of $1.34.

Paul A. Romness, President and CEO of OS Therapies Inc., was granted options to purchase 1,000,000 shares of the company's common stock.

OS Therapies Inc. Director Olivier Roger Jarry received a grant of 50,000 stock options with an exercise price of $1.34, vesting on the one-year anniversary of the grant date.

OS Therapies Incorporated announces its 2026 Annual Meeting of Stockholders, to be held virtually on September 9, 2026, with key proposals including director elections and incentive plan amendments.

OS Therapies Incorporated adjourned its 2025 annual meeting to October 21, 2025, to solicit additional proxies, while also releasing an investor presentation detailing its clinical pipeline and strategic milestones.

OS Therapies Incorporated has filed definitive additional proxy materials with the SEC.

OS Therapies Incorporated will hold its 2025 Annual Meeting to vote on key proposals including director elections, a significant share issuance for an asset acquisition, and an increase in authorized capital stock.

OS Therapies Inc. adjourned its Special Meeting of Stockholders on March 31, 2025, due to the absence of a quorum and will reconvene on April 9, 2025.

OS Therapies Incorporated is seeking stockholder approval for the potential issuance of common stock exceeding 20% of outstanding shares related to the conversion of preferred stock and exercise of warrants from a recent private placement.

OS Therapies Incorporated filed an S-1 registration statement to allow selling stockholders to resell up to 3.76 million common shares issued from a recent warrant exercise inducement, which generated over $4.2 million in gross proceeds for the company.

OS Therapies Incorporated has filed an S-1 registration statement to allow selling stockholders to resell up to 7.5 million shares, following positive Phase IIb clinical trial results for its lead Osteosarcoma drug candidate, OST-HER2, and the strategic acquisition of new immune-oncology assets.

OS Therapies is registering for resale up to 10.8 million common shares, representing securities issuable from a recent private placement involving convertible preferred stock and warrants.

OS Therapies aims to register the resale of up to $15 million in common stock through an equity line of credit, alongside commitment shares.

OS Therapies Incorporated has filed an amendment to its registration statement for the resale of up to $15 million in common stock through an equity line of credit with Square Gate Capital Master Fund, LLC.

OS Therapies has filed a registration statement for the resale of up to $15 million in common stock by Square Gate Capital Master Fund, LLC, following an equity line of credit agreement.

Shalom Auerbach and Einodmil LLC updated their beneficial ownership in OS Therapies Inc, reporting a slight reduction in Einodmil's stake through an open market sale.

Einodmil LLC, a significant beneficial owner of OS Therapies Inc, has reported the sale of 142,012 shares of common stock in April and May 2025, reducing its stake to 9.8%.

Shalom Auerbach and Einodmil LLC have filed an Amendment No. 2 to their Schedule 13D, updating their beneficial ownership in OS Therapies Inc. and clarifying past transactions following an SEC comment letter.

Shalom Auerbach and Einodmil LLC have updated their beneficial ownership in OS Therapies Inc, reflecting an increase in shares held by Einodmil LLC through an additional transfer, while also disclosing a recent sale of shares.

Shalom Auerbach and Einodmil LLC have filed a Schedule 13D, revealing beneficial ownership of 11.9% and 11.8% respectively in OS Therapies Incorporated, detailing share acquisitions through note conversions and a strategic transfer agreement tied to the company's IPO.

Thomas A. Satterfield, Jr. has increased his beneficial ownership in OS Therapies Incorporated to 9.4% of common stock, including convertible preferred shares and warrants.

Ayala Pharmaceuticals, Inc. has filed a Schedule 13G, reporting a 9.99% beneficial ownership stake in OS Therapies Incorporated, holding 2,164,215 shares of common stock.

Thomas A. Satterfield, Jr. has filed an amended Schedule 13G, reporting a 5.9% beneficial ownership stake in OS Therapies Incorporated as of December 31, 2024.